American Academy of Neurology Annual Meeting 2013 PRESENTATIONS and POSTERS Presentation Wed, 20 Mar 4:00‐5:30 PM S31.005 An Exploratory Analysis of Magnetic Resonance Imaging Outcomes in the DreaMS Trial: A Double‐Blind, Placebo‐Controlled, Phase 2, 26‐Week Trial of a Selective Sphingosine 1‐Phosphate Receptor Agonist ONO‐4641 in Patients with Relapsing– Remitting Multiple Sclerosis Krzysztof Selmaj, Frauke Zipp, Timothy Vollmer, Amit Bar‐ Or, Bryan Due, Johan Van Beek, Kathinathan Thangavelu Poster Sessions Session 1 Mon, 18 Mar 2:00‐6:30 PM PD1.005 Cramp‐Fasciculation Syndrome in Patients with and without Neural Autoantibodies Teerin Liewluck, Christopher Klein, Lyell Jones P01.165 Long‐Term Safety of Fingolimod in Patients with Relapsing‐Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study Timothy Vollmer, Douglas Jeffery, Douglas Goodin, Ludwig Kappos, Fred Lublin, Ernst‐Wilhelm Radue, Kottil Rammohan, Anthony Reder, Mark Agius, Tracy Stites, Bingbing Li, Linda Cappiello, Philipp von Rosenstiel, Peter Calabresi Session 2 Tues, 19 Mar 7:30 AM‐12 Noon P02.005 Lasting Relief from Chronic Pain after Cerebral Infarction Haley Burke, Al Anderson, Christopher Filley Session 3 Tues, 19 Mar 2:00‐6:30 PM P03.201 Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National US Estimates Jonathan Campbell, Vahram Ghushchyan, R. Brett McQueen, Sharon Cahoon‐Metzger, Terrie Livingstone, Timothy Vollmer, John Corboy, Augusto Miravalle, Teri Schreiner, Kavita Nair P03.212 Daclizumab High‐Yield Process Treatment Reduced the Impact of Multiple Sclerosis Relapse on Health‐Related Quality of Life (Results of the SELECT Trial) Timothy Vollmer, Eva Havrdova, Krzysztof Selmaj, Jacob Elkins, Steven Hass, Shien Guo, Irina Proskorovsky, Glenn Phillips P03.233 Co‐Stimulatory Molecule CD40 Is Elevated in Type I Diabetes and Multiple Sclerosis Compared to Controls Teri Schreiner, Dan Waid, James Yarovoy, David Wagner, John Corboy P03.267 An Ongoing Randomized, Double‐Blind, Placebo‐Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity Due to Multiple Sclerosis Timothy Vollmer, Dan Chen, Patricia Nance, Aaron Ellenbogen, Stephen Flitman, James Garrison, John Huddlestone, Cynthia Huffman, Angeli Mayadev, Nirav Patel, James Patton, Ben Thrower, Dmitri Lissin Session 5 Wed, 20 Mar 2:00‐7:00 PM P05.153 Effect of the Sphingosine 1‐Phosphate Receptor Agonist ONO‐4641 on Circulating Lymphocytes in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Phase 2 DreaMS Trial Amit Bar‐Or, Frauke Zipp, Selmaj Krzysztof, Bryan Due, Timothy Vollmer P05.249 Disparities in Stroke Epidemiology between Two University Hospitals in Mexico and United States Mario Cerdan‐Trevino, Leonel Cantu‐Martinez, Angel Pulido, Alexandra Graves, Hector Martinez, William Jones Session 6 Thur, 21 Mar 7:30 AM‐12 Noon P06.073 Callosal Disconnection and Limb‐Kinetic Apraxia Lealani Acosta, Jeffrey Bennett, Kenneth Heilman P06.193 Guillain‐Barré Syndrome after West Nile Infection: A Case Report Wesley Reynolds, Matthew West, Mario Cerdan‐Trevino, Dianna Quan, Kenneth Tyler Session 7 Thur, 21 Mar 2:00‐7:00 PM P07.102 Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing‐ Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis Douglas Goodin, Douglas Jeffery, Ludwig Kappos, Fred Lublin, Ernst‐Wilhelm Radue, Kottil Rammohan, Anthony Reder, Timothy Vollmer, Mark Agius, Tracy Stites, Bingbing Li, Linda Cappiello, Philipp von Rosenstiel, Peter Calabresi P07.093 Alemtuzumab Reduces MS Disease Activity in Active Relapsing‐Remitting Multiple Sclerosis Patients Who Had Disease Activity on Prior Therapy Hans Hartung, Timothy Vollmer, Douglas Arnold, Jeffrey Cohen, Alasdair Coles, Christian Confavreux, Edward Fox, Eva Havrdova, Krzysztof Selmaj, Howard Weiner, Cary Twyman, Tamara Miller, Stephen Lake, David Margolin, Michael Panzara, Alastair Compston